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Essentials
• Genetic variants controlling gene regulation have not been explored in pharmacogenomics.
• We tested liver expression quantitative trait loci for association with warfarin dose response.
• A novel predictor for increased warfarin dose response in African Americans was identified.
• Precision medicine must take into account populationspecific variation in gene regulation.
Summary. Background: Warfarin is commonly used to control and prevent thromboembolic disorders. However, because of warfarin's complex dose-requirement relationship, safe and effective use is challenging. Pharmacogenomics-guided warfarin dosing algorithms that include the well-established VKORC1 and CYP2C9 polymorphisms explain only a small proportion of inter-individual variability in African Americans (AAs). Objectives: We aimed to assess whether transcriptomic analyses could be used to identify regulatory variants associated with warfarin dose response in AAs. Patients/Methods: We identified a total of 56 expression quantitative trait loci (eQTLs) for CYP2C9, VKORC1 and CALU derived from human livers and evaluated their association with warfarin dose response in two independent AA warfarin patient cohorts. Results:
We found that rs4889606, a strong cis-eQTL for VKORC1 (log 10 Bayes Factor = 12.02), is significantly associated with increased warfarin daily dose requirement (b = 1.1; 95% confidence interval [CI] 0.46 to 1.8) in the discovery cohort (n = 305) and in the replication cohort (b = 1.04; 95% CI 0.33 À1.7; n = 141) after conditioning on relevant covariates and the VKORC1 -1639G>A (rs9923231) variant. Inclusion of rs4889606 genotypes, along with CYP2C9 alleles, rs9923231 genotypes and clinical variables, explained 31% of the inter-patient variability in warfarin dose requirement. We demonstrate different linkage disequilibrium patterns in the region encompassing rs4889606 and rs9923231 between AAs and European Americans, which may explain the increased dose requirement found in AAs. Conclusion: Our approach of interrogating eQTLs identified in liver has revealed a novel predictor of warfarin dose response in AAs. Our work highlights the utility of leveraging information from regulatory variants mapped in the liver to uncover novel variants associated with drug response and the importance of population-specific research.
Introduction
Warfarin is an effective anticoagulant for the prevention and treatment of thrombotic disease. However, because of its narrow therapeutic window and large variation in therapeutic warfarin dose requirement between individuals, there can be significant adverse effects [1] . Although new oral anticoagulants (NOACs) have been developed, there are several advantages in continuing to administer warfarin to patients, such as extensive familiarity, wellestablished form of monitoring (international normalized ratio), treatment of valvular atrial fibrillation and cost [2, 3] . Furthermore, in many countries outside of the USA, NOACs are covered only for patients with poor anticoagulation control on vitamin K antagonists (VKAs) [3] . Therefore, warfarin will remain a key drug in the treatment of thrombotic disease. As such, identification of polymorphisms associated with warfarin dose response will continue to be of importance in determining safe and effective doses for individual patients.
In the liver, warfarin is primarily metabolized by CYP2C9 and exerts its anticoagulant effect by inhibiting VKOR (encoded by VKORC1), leading to reduced amounts of vitamin K available to serve as a cofactor for clotting proteins [4, 5] . Polymorphisms in CYP2C9 and VKORC1 have been well established in warfarin dose requirement [6] . However, these polymorphisms explain significantly less of the variance in dose among African Americans (AAs) compared with Caucasians (8% vs. 35%, respectively), which may be due to a lower frequency of the minor alleles of CYP2C9*2, CYP2C9*3 and VKORC1 -1639G>A among AAs [7] [8] [9] [10] . Several other genetic variants in other genes have also been implicated as influencing warfarin dose requirement. Among these are single nucleotide polymorphisms (SNPs) in CYP4F2, which metabolizes vitamin K, thereby limiting its availability, and CALU, a cofactor in the VKOR complex [11, 12] . However, studies have shown a lack of association between CYP4F2 genotypes and therapeutic warfarin dose in AAs [13, 14] .
Despite substantial efforts, identification of novel polymorphisms associated with warfarin dose response has been limited. Several genome-wide studies have mapped variants that correlate with expression levels of genes known as expression quantitative trait loci (eQTL) [15] [16] [17] [18] , which may provide a framework for identifying novel variants associated with complex traits, including drug response [18] . Because coagulation factors and warfarin are primarily synthesized and metabolized in the liver, respectively, the study of eQTLs derived from human livers is a more suitable analysis for the identification of regulatory variation that may affect warfarin dose requirement.
With this in mind, we have examined additional common genetic variation (minor allele frequency ≥ 5%) that may be predictive of therapeutic warfarin dose in AAs using eQTL analysis conducted in human livers. We focused on eQTLs for the candidate genes, CYP2C9, VKORC1 and CALU, given their role and previous association in warfarin dose response in AAs. The goal of the present study is to utilize regulatory variants derived from human livers in order to identify novel genetic variants associated with warfarin dose requirement in AAs. We performed a two-stage analysis to test the association between previously identified eQTLs for CYP2C9, VKORC1 and CALU and warfarin dose response among AAs in a discovery cohort, followed by examination of the most significant eQTLs in an independent replication cohort.
Materials and methods

African American patient cohorts
Participants in the discovery (n = 306) and replication (n = 141) cohorts were unrelated, self-described as AA, age ≥ 18 years, and on a stable dose of warfarin defined as the same dose for at least three consecutive clinic visits that produced an international normalized ratio (INR) within the therapeutic range of 2-3. Data related to warfarin dose requirement included age, height, weight, ethnicity, gender, liver disease and chronic kidney disease defined as an estimated glomerular filtration rate, stable warfarin dose, INR at stable warfarin dose, indication for warfarin therapy, and other medications taken, including potentially interacting drugs. Patients were recruited from The University of Chicago, University of Illinois at Chicago, The George Washington University Medical Faculty Associates and the Veterans Affairs Hospital in Washington, DC. The replication cohort was independent of the discovery cohort and consisted of patients enrolled from the same institutions. The study was conducted according to the principles of the Declaration of Helsinki. The institutional review board approved the study and written informed consent was obtained from all the study participants.
Identification and selection of liver eQTLs
To determine liver eQTLs for our candidate genes, we conducted a bioinformatics analysis of publicly available data from the Gene Expression Omnibus, accession numbers GSE9588 and GSE26106 (http://www.ncbi.nlm.nih. gov/geo) [16, 19] . Cis-and trans-acting eQTLs were identified using a method similar to that previously described by Innocenti et al. [19] . Briefly, SNPs within 250 kb to the transcription start site of the associated gene were classified as cis-eQTLs. All other associations were considered candidate trans-eQTLs. Log 10 -transformed Bayes factor (log 10 BF) was used to infer genotype-trait association rather than a P-value in order to assess the evidence that a given SNP is an eQTL for a given gene, as previously described [20] .
GSE9588 and GSE26106 are primarily comprised of liver tissue from Caucasian participants. To account for the differences in linkage disequilibrium (LD) structure between AAs and Caucasians, and to identify independent eQTL associations among AAs, we conducted LD pruning with phased genotype data from the African ancestry in the southwest USA (ASW) population in HapMap 3 release 2. Pairwise LD betweenVKORC1 -1639G>A rs9923231, the known predictive VKORC1 SNP for warfarin dose, and the VKORC1 cis-eQTLs was calculated in the same fashion utilizing SNAP version 2.2 [21] .
Genotyping
Study participants provided a DNA sample (whole-blood, saliva or mouthwash sample) and genomic DNA was isolated as previously described [22] . eQTLs with a log 10 BF ≥ 3 were genotyped using either Sequenom Massarray or TaqMan assays according to the manufacturer's instructions. SNPs, which failed genotyping because of multiplexing constraints, were genotyped via predesigned TaqMan SNP assays (Applied Biosystems, Foster City, CA, USA). Patients were also genotyped for the known genetic variants rs9923231 (VKORC1 -1639), rs1799853 (CYP2C9*2), rs1057910 (CYP2C9*3), rs28371686 (CYP2C9*5), rs7900194 (CYP2C9*8) and rs28371685 (CYP2C9*11) using previously published methods [23] [24] [25] . In addition, a panel of 105 ancestry informative markers (AIMs) was genotyped for each patient to determine West African ancestry (WAA) using Sequenom Massarray as previously described [26] .
Quality control
SNPs genotyped in both cohorts were excluded based on genotyping rate <90%, minor allele frequency of <5% and failed Hardy-Weinberg equilibrium (HWE) testing at a P-value <0.0001. To test for departures from HWE, we utilized the Fisher's exact test implemented in PLINK [27] . Three SNPs were removed due to failing quality control (QC) thresholds. Samples with SNP call rates <90% across all SNPs were excluded. Only one individual in the discovery cohort did not meet QC thresholds, resulting in 305 samples included in the analysis. All QC steps were conducted using PLINK [27] .
Statistical analysis
For both cohorts, the Kolmogorov-Smirnov test was used to test for normality and weekly warfarin dose values were log 2 -transformed before statistical modeling to achieve an approximate normal distribution. Pearson's correlation was used to identify clinical factors associated with weekly warfarin dose (mg). All covariates were tested as single covariates for association with therapeutic weekly warfarin dose using the IBM SPSS Statistics version 19.0.0 package (SPSS, Chicago, IL, USA). In order to identify SNP associations independent of the wellknown variants associated with warfarin dose response, analysis of VKORC1 and CYP2C9 eQTLs were conditioned for VKORC1 -1639G>A rs9923231 and presence of CYP2C9*2, *3, *5, *8 and *11 alleles (CYP2C9 star alleles), respectively. We combined the CYP2C9*2, *3, *5, *8 and *11 variants into a single group of CYP2C9 star alleles, on the basis of earlier data [28] . Individual ancestry estimates were obtained from STRUCTURE 2.3.3 as previously described [29] .
Linear regression was used to test the association between SNPs and warfarin dose response adjusting for age, weight and indication of DVT or PE. Statistically significant SNPs in the discovery cohort were then genotyped in the replication cohort for validation. All SNP association analyses were conducted in PLINK [27] . Statistical significance for association refers to a P-value ≤ 0.00087 for the discovery cohort reflecting Bonferroni correction (0.05/57) to account for multiple testing and P-value ≤ 0.05 for the replication cohort because only one SNP met the criteria for replication. The effects of genetic and non-genetic factors on therapeutic warfarin dose variability were assessed by multivariate analysis. Clinical variables included in the analysis were age, weight and deep vein thrombosis and/or pulmonary embolism (DVT/PE). Presence of CYP2C9*2, *3, *5, *8 and *11 alleles were coded as 0 for wild-type and 1 for variant carrier; VKORC1 -1639G>A rs9923231 was coded as 0 for GG, 1 for GA and 2 for AA; and rs4889606 was coded as 0 for AA, 1 for GA and 2 for GG.
Results
Demographic and clinical characteristics for the discovery and replication cohorts are provided in Table 1 . Mean therapeutic weekly warfarin dose and INR for the discovery cohort were 44.9 AE 18.7 mg and 2.47 AE 0.36, respectively (Table 1) . For the replication cohort, the mean therapeutic weekly warfarin dose and INR were 45.4 AE 15.9 mg and 2.38 AE 0.38, respectively ( Table 1) . The majority of patients were taking warfarin due to DVT/PE (> 50% in each cohort; Table 1 ). Mean age was slightly lower for the discovery cohort compared with the replication cohort (57.62 AE 15.7 and 62.12 AE 16.5, respectively; P = 0.001). The replication cohort consisted of significantly more men (52.9%, P < 0.01) compared with the discovery cohort and may explain the significantly higher mean weight and height observed (100.78 AE 36.0 and 171.27 AE 11.4; P = 0.009 and 0.002, respectively; Table 1 ). Percentage of WAA was significantly higher in the discovery cohort compared with the replication cohort (81.4% and 77.2%, respectively, P = 0.001; Table 1 ). Allele frequencies for CYP2C9 star alleles and VKORC1 -1639 are similar between the cohorts and were in HWE (Table 1) . Although some demographic characteristics were significantly different between the discovery and the replication cohorts, participants were recruited from the same population and had the same phenotype, furthermore, the same methods were applied. As expected, age was inversely associated with warfarin dose requirement in both the discovery and replication cohorts (P < 0.001; Table 2 ). We found that warfarin dose requirement increased with increasing weight in the discovery and replication cohorts (P < 0.001 and P = 0.003, respectively; Table 2 ). The association between height and warfarin dose requirement was only significant in the discovery cohort (P = 0.0004; Table 2 ). However, this association was lost when we accounted for weight in our analysis. DVT/PE as a primary indication for warfarin therapy was significantly associated with warfarin dose requirement in both cohorts (P = 0.001; Table 2 ). Neither percentage of WAA or sex was associated with warfarin dose requirement (P > 0.05) in either cohort (Table 2) . Age, weight and DVT/PE were included as covariates for all associations between genetic markers and warfarin dose response.
A total of 56 eQTLs identified from human livers were genotyped in the discovery cohort (Tables 3 and S1-S3) . Analysis of five cis-and six trans-eQTLs for CALU did not uncover a significant association with warfarin dose response (Table S1 ). In addition to CALU eQTLs, we also genotyped the CALU SNP rs339097 because of its previous association with warfarin dose response among AAs [30] . However, rs339097 was not associated with warfarin dose response in the discovery cohort (P = 0.61; Table S1 ), which is consistent with previous findings [25] . For CYP2C9, we evaluated the association between 12 trans-eQTLs and warfarin dose response (Table S2) . After conditioning on the presence of any CYP2C9 star allele, none of the CYP2C9 eQTLs remained associated with warfarin dose response (Table S2) .
We identified 32 VKORC1 eQTLs, among which VKORC1 -1639G>A rs9923231, rs749670, rs4889606 and rs9926533 were strongly associated, in cis, with VKORC1 gene expression (log 10 BF ≥ 12.0; Table S3 ). In the discovery and replication cohorts, the known warfarin dose polymorphism VKORC1 -1639G>A rs9923231 was significantly associated with lower warfarin dose (P = 8.46 9 10 À9 and P = 0.0002, respectively; data not shown) after adjusting for covariates. Consequently, for the VKORC1 eQTLs, we carried out conditional analysis, which included SNP VKORC1 -1639G>A rs9923231 in addition to age, weight and presence of DVT/PE. Only one eQTL, rs4889606, reached corresponding Bonferronicorrected significance and was associated with increased warfarin dose requirement in the discovery cohort (P = 7.18 9 10
À6
; Table 4 ). This association was further validated in the replication cohort with matching direction of effect and increased warfarin dose response (P = 0.01; Table 4 ). The association of daily stable warfarin dose requirement and rs4889606 genotypes is shown in Fig. 1 . The daily warfarin dose was significantly different among the three genotypes of rs4889606, with carriers of the AG or GG genotypes requiring higher doses (6.8 AE 3.1 and 7.6 AE 3.9 mg day À1 , respectively) compared with AA carriers in the discovery cohort (b = 1.1; 95% CI = 0.46-1.8; P = 0.0009). This increase in daily warfarin dose requirement for AG or GG carriers (6.8 AE 2.3 and 8.6 AE 3.1, respectively) was also found in the replication cohort (b = 1.04; 95% CI = 0.33-1.7; P = 0.005; Fig. 1 ). We also found that SNPs rs4889606 and VKORC1 -1639G>A rs9923231 were not in LD in either the discovery or replication cohorts (r 2 = 0.17 and r 2 = 0.08, respectively; Table 4 ), which may explain the increased warfarin dose requirement observed for rs4889606 among AAs. Table 5 displays the results of the multiple regression models for the discovery and replication cohorts. The clinical variables alone (age, weight and presence of DVT/PE) explained 20% and 13% of the variability in warfarin dose requirement for the discovery and replication cohorts, respectively (adjusted R 2 ; Table 5 ). Inclusion of the CYP2C9 *2, *3, *5, *8 and *11 alleles and VKORC1 -1639G>A genotypes in the clinical only model increased the explained variance in warfarin dose requirement to 30% and 28%, respectively. For both the discovery and replication cohorts a modest increase to 31% in explained dose variability was observed in the model with the addition of the rs4889606 genotypes, while accounting for clinical and previously associated genetic predictors (Table 5) .
Utilizing HapMap data for ASW (African American) and CEU (European American [EA]) populations we generated LD plots for the region between STX1B2 and VKORC1, which encompasses SNPs rs4889606 and VKORC1 -1639G>A rs9923231. Pairwise LD analysis revealed differences in sizes and patterns of LD blocks (defined as r 2 ≥ 0.8) between ASW and EA populations (Fig. S1 ). Among ASW, we found four haplotype blocks across this region (Fig. S1A) . The well-known VKORC1 eQTLs, VKORC1 -1639G>A rs9923231 and rs9934438, which are associated with lower warfarin dose requirement, are in high LD and therefore on the same haplotype block extending 10 kb (Fig. S1A) . In contrast, LD is disrupted and SNP rs4889606 is not found on a haplotype block, further supporting our finding that the increased warfarin dose requirement associated with rs4889606 is independent of rs9923231 among ASW (Fig. S1A) . In contrast, among EAs a relative strong LD pattern was observed between rs4889606, VKORC1 -1639G>A rs9923231 and rs9934438, which resulted in a 98 kb haplotype block encompassing the entire region (Fig. S1B) .
Discussion
Our study has identified a novel association with increased warfarin dose requirement among AAs. Warfarin dose requirement has been shown to vary by race, with AAs requiring higher doses [31, 32] . Personalized warfarin dosing, generated from algorithms based on genetic and clinical factors, has been proposed to improve dosing accuracy and reduce the risk of sub-or supra-therapeutic anticoagulation [7, 33] . The identification of biologically relevant genetic variation in warfarin dose requirement is essential in personalized medicine, and hence the inclusion of transcriptomic data was used to identify novel variants associated with warfarin dose response. In pharmacogenomics, the liver is the most relevant tissue in which to perform eQTL analysis, which can provide candidate loci for prospective clinical studies. As such, genetic variants that are significantly associated with gene expression may have a putative functional role in drug disposition and response [34] . Through publicly available data, we have identified 56 eQTLs derived from human livers that significantly affect CYP2C9, VKORC1 or CALU gene expression and tested their association with therapeutic warfarin dose requirement in AAs.
The most significant finding in our study is the association of the minor allele of rs4889606 (G) with higher warfarin dose requirement in two independent AA warfarin patient cohorts, which remained significant after conditioning on VKORC1 -1639G>A rs9923231 and clinical factors (Table 4) . We demonstrate that carriers of the AG Controlling for age, weight and deep vein thrombosis/pulmonary embolism and conditioned for rs9923231. Chr, chromosome; SNP, single nucleotide polymorphism; MA, minor allele; MAF, minor allele frequency; CI, confidence interval. *r2/D 0 between rs4889606 and rs9923231. exp(b) < 1 reflects a decrease. exp(b) > 1 reflects an increase. 95% CI is for b. Bonferroni correction is set to a P-value ≤ 0.00087 and P ≤ 0.05 for the discovery and replication cohorts, respectively. and GG genotypes require a significantly higher daily warfarin dose compared with AA carriers in both the discovery and replication cohorts (Fig. 1) . The inclusion of rs4889606 genotypes along with clinical variables, CYP2C9 star alleles and VKORC1 -1639G>A genotype, modestly increased the proportion of variability in warfarin dose requirement explained in AAs (Table 5) . This model explained 31% of the inter-patient variability in warfarin dose requirement in both cohorts. In AAs, most of the variability in warfarin dose requirement remains unaccounted for. Our study provides evidence that supports the inclusion of regulatory genetic variants beyond the previously associated CYP2C9 and VKORC1 variants in efforts to discover variants associated with warfarin dose response among AAs. SNP rs4889606 is located within the intron 6 of STX1B, which is approximately 98 kb downstream of the VKORC1 gene and has a minor allele frequency of 21% and 22% in the discovery and replication cohorts, respectively (Table 4) . VKORC1 variation has long been known to be associated with warfarin dose requirement and SNPs VKORC1 -1639G>A rs9923231 and rs9934438 (which are in high LD) are the most well-established SNPs at this locus associated with lower warfarin dose requirement across ethnicities [35] . We demonstrate that in both the discovery and replication cohorts, there is very low LD between SNPs rs4889606 and VKORC1 -1639G>A rs9923231 (r 2 ≤ 0.17, Table 4 ). When comparing LD patterns in the STX1B and VKORC1 region encompassing rs4889606 and VKORC1 -1639G>A rs9923231 between those with African ancestry in the southwest USA (ASW) and Utah residents with ancestry from northern and western Europe (CEU) (HapMap populations), we observed shorter stretches of LD among ASW resulting in four blocks of LD, but one large LD block is seen that extends from the STX1B2 gene into the VKORC1 gene among CEU (Fig. S1A and 1B, respectively) . Furthermore, the minor allele (G) at rs4889606 is associated with higher warfarin dose, whereas the VKORC1 -1639G>A rs9923231 minor allele (A) is associated with lower warfarin dose requirement in our cohorts, suggesting an independent effect of this SNP from VKORC1 -1639G>A rs9923231. It is important to note that according to the 1000 Genomes data, rs4889606 is in complete LD with rs12716979 (also located in intron 6 of STX1B; r 2 = 1) and in high LD with rs11441998 (within Intron 3 of STX1B; r 2 = 0.8). The association of rs4889606 with higher warfarin dose requirement in AAs provides a more comprehensive Clinical variables: age, weight and deep vein thrombosis/pulmonary embolism . CYP2C9 star alleles include *2, *3, *5, *8 and *11 alleles and were included as predictors with two levels (wild-type = 0 and variant carrier = 1). rs9923231 was coded as 0 for GG, 1 for GA and 2 for AA. rs4889606 was coded as 0 for AA, 1 for GA and 2 for GG. Variables were retained in the model if they achieved statistical significance (P ≤ 0.05) or were marginally significant (0.05 < P ≤ 0.10) with strong biological plausibility.
understanding of the genetic landscape in dose variability and may help explain differences in warfarin dose requirement between populations. A recent genome-wide association study found rs4889606 to be associated with warfarin dose response in a Brazilian cohort (P = 1.0 9 10
À29
) but after conditioning on the study's top signal (rs749671, which is in complete LD with VKORC1 -1639G>A rs9923231in Brazilians [r 2 = 0.98]), it was no longer significant [36] . In a more recent study among Egyptians and European Americans on stable warfarin dose, rs4889606 was found to be a significant determinant of warfarin dose requirement in both populations [37] . Once again, rs4889606 was no longer significant after conditioning for rs9923231 as a result of the high LD observed between rs4889606 and rs9923231 among the Egyptian and European American cohorts [37] . Hamadeh et al. also report that AIMs for the Egyptian cohort were not available to confirm WAA; nonetheless, they found that the STX1B haplotype block in Egyptians highly resembled that of European Americans [37] . A limitation of our study was the relatively small sample size for both the discovery cohort and the replication cohort. In addition, rs4889606 was identified as a strong VKORC1 ciseQTL from predominantly Caucasian liver samples (~90%) and because of the lack of liver eQTL data from AAs, we cannot determine if rs4889606 is also a VKORC1 liver eQTL in AAs. To identify potentially regulatory functions, we used HaploReg and found that SNP rs4889606 overlaps with promoter and enhancer histone marks in multiple tissues, including liver tissues, and is located in a DNase hypersensitive region [38] . These results strongly suggest that rs4889606 is located in a regulatory sequence.
In conclusion, our unique approach of interrogating liver eQTLs for CALU, CYP2C9 and VKORC1 led to the identification of a novel SNP associated with higher warfarin dose requirement in AAs. SNP rs4889606 is downstream of VKORC1 and has a putative regulatory role. By using the decreased LD structure found in populations of African ancestry, we were able to disentangle the association of the well-established VKORC1 variant, VKORC1 -1639G>A rs9923231, with other regulatory variants in this population. Our study suggests that an eQTL-based strategy can be an efficient way of discovering novel associations with drug response. Our study utilized known regulatory variation to identify genetic variation associated with warfarin dose requirement and further highlights the unique genetic discoveries that are possible with populations of African ancestry.
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